메뉴 건너뛰기




Volumn 33, Issue SUPPL. 1, 2007, Pages

Immunosuppressive treatment strategies in low-risk MDS

Author keywords

Antithymocyte globulin; ATG; Ciclosporin A; Hypoplastic MDS; Immunomodulation; Immunosuppression; Low risk MDS; Myelodysplastic syndrome

Indexed keywords

CYCLOSPORIN A; CYTOKINE; ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; HLA DR15 ANTIGEN; LENALIDOMIDE; LYMPHOCYTE ANTIBODY; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

EID: 35848960369     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2007.07.003     Document Type: Article
Times cited : (2)

References (32)
  • 1
    • 0030897009 scopus 로고    scopus 로고
    • International scoring system for evaluating prognosis in myelodysplastic syndromes
    • Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 89 (1997) 88-2079
    • (1997) Blood , vol.89 , pp. 88-2079
    • Greenberg, P.1    Cox, C.2    LeBeau, M.M.3
  • 2
    • 0029020851 scopus 로고
    • Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes
    • Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 86 (1995) 76-268
    • (1995) Blood , vol.86 , pp. 76-268
    • Raza, A.1    Gezer, S.2    Mundle, S.3
  • 3
    • 0029957664 scopus 로고    scopus 로고
    • Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells
    • Rajapaksa R., Ginzton N., Rott L.S., and Greenberg P.L. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 88 (1996) 84-4275
    • (1996) Blood , vol.88 , pp. 84-4275
    • Rajapaksa, R.1    Ginzton, N.2    Rott, L.S.3    Greenberg, P.L.4
  • 4
    • 0030926080 scopus 로고    scopus 로고
    • Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes
    • Bouscary D., De Vos J., Guesnu M., et al. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia 11 (1997) 45-839
    • (1997) Leukemia , vol.11 , pp. 45-839
    • Bouscary, D.1    De Vos, J.2    Guesnu, M.3
  • 5
    • 0035146787 scopus 로고    scopus 로고
    • Excessive apoptosis in low risk myelodysplastic syndromes (MDS)
    • Parker J.E., and Mufti G.J. Excessive apoptosis in low risk myelodysplastic syndromes (MDS). Leuk Lymphoma 40 (2000) 1-24
    • (2000) Leuk Lymphoma , vol.40 , pp. 1-24
    • Parker, J.E.1    Mufti, G.J.2
  • 6
    • 0036848438 scopus 로고    scopus 로고
    • More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia
    • Huh Y.O., Jilani I., Estey E., et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia 16 (2002) 52-2249
    • (2002) Leukemia , vol.16 , pp. 52-2249
    • Huh, Y.O.1    Jilani, I.2    Estey, E.3
  • 8
    • 28044465152 scopus 로고    scopus 로고
    • Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis
    • Stifter G., Heiss S., Gastl G., Tzankov A., and Stauder R. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis. Eur J Haematol 75 (2005) 91-485
    • (2005) Eur J Haematol , vol.75 , pp. 91-485
    • Stifter, G.1    Heiss, S.2    Gastl, G.3    Tzankov, A.4    Stauder, R.5
  • 9
    • 0031656518 scopus 로고    scopus 로고
    • A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome
    • Gersuk G.M., Beckham C., Loken M.R., et al. A role for tumour necrosis factor-alpha, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 103 (1998) 88-176
    • (1998) Br J Haematol , vol.103 , pp. 88-176
    • Gersuk, G.M.1    Beckham, C.2    Loken, M.R.3
  • 10
    • 0037388243 scopus 로고    scopus 로고
    • Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases
    • Sashida G., Ohyashiki J.H., Nakajima A., et al. Telomere dynamics in myelodysplastic syndrome determined by telomere measurement of marrow metaphases. Clin Cancer Res 9 (2003) 96-1489
    • (2003) Clin Cancer Res , vol.9 , pp. 96-1489
    • Sashida, G.1    Ohyashiki, J.H.2    Nakajima, A.3
  • 11
    • 85046523148 scopus 로고    scopus 로고
    • Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia
    • Kurotaki H., Tsushima Y., Nagai K., and Yagihashi S. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 102 (2000) 23-115
    • (2000) Acta Haematol , vol.102 , pp. 23-115
    • Kurotaki, H.1    Tsushima, Y.2    Nagai, K.3    Yagihashi, S.4
  • 12
    • 0020574146 scopus 로고
    • Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia
    • Francis G.E., Wing M.A., Miller E.J., Berney J.J., Wonke B., and Hoffbrand A.V. Use of bone marrow culture in prediction of acute leukaemic transformation in pre-leukaemia. Lancet I (1983) 12-1409
    • (1983) Lancet , vol.I , pp. 12-1409
    • Francis, G.E.1    Wing, M.A.2    Miller, E.J.3    Berney, J.J.4    Wonke, B.5    Hoffbrand, A.V.6
  • 13
    • 0037111548 scopus 로고    scopus 로고
    • Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression
    • Kochenderfer J.N., Kobayashi S., Wieder E.D., Su C., and Molldrem J.J. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 100 (2002) 45-639
    • (2002) Blood , vol.100 , pp. 45-639
    • Kochenderfer, J.N.1    Kobayashi, S.2    Wieder, E.D.3    Su, C.4    Molldrem, J.J.5
  • 14
    • 0036229652 scopus 로고    scopus 로고
    • A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome
    • Maciejewski J.P., Risitano A.M., Sloand E.M., et al. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol 117 (2002) 26-119
    • (2002) Br J Haematol , vol.117 , pp. 26-119
    • Maciejewski, J.P.1    Risitano, A.M.2    Sloand, E.M.3
  • 15
    • 0036174925 scopus 로고    scopus 로고
    • Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes
    • Stasi R., and Amadori S. Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. Br J Haematol 116 (2002) 7-334
    • (2002) Br J Haematol , vol.116 , pp. 7-334
    • Stasi, R.1    Amadori, S.2
  • 17
    • 0037031289 scopus 로고    scopus 로고
    • Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes
    • Molldrem J.J., Leifer E., Bahceci E., et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 137 (2002) 63-156
    • (2002) Ann Intern Med , vol.137 , pp. 63-156
    • Molldrem, J.J.1    Leifer, E.2    Bahceci, E.3
  • 18
    • 0345701967 scopus 로고    scopus 로고
    • A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk' myelodysplasia
    • Killick S.B., Mufti G., Cavenagh J.D., et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with low-risk' myelodysplasia. Br J Haematol 120 (2003) 84-679
    • (2003) Br J Haematol , vol.120 , pp. 84-679
    • Killick, S.B.1    Mufti, G.2    Cavenagh, J.D.3
  • 19
    • 1542608520 scopus 로고    scopus 로고
    • A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes
    • Stadler M., Germing U., Kliche K.O., et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes. Leukemia 18 (2004) 5-460
    • (2004) Leukemia , vol.18 , pp. 5-460
    • Stadler, M.1    Germing, U.2    Kliche, K.O.3
  • 20
    • 0031888417 scopus 로고    scopus 로고
    • Ciclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow
    • Janasova A., Neuwirtova R., Cermak J., et al. Ciclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100 (1998) 9-304
    • (1998) Br J Haematol , vol.100 , pp. 9-304
    • Janasova, A.1    Neuwirtova, R.2    Cermak, J.3
  • 21
    • 0242643661 scopus 로고    scopus 로고
    • Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes
    • Yazji S., Giles F.J., Tsimberidou A.M., et al. Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia 17 (2003) 6-2101
    • (2003) Leukemia , vol.17 , pp. 6-2101
    • Yazji, S.1    Giles, F.J.2    Tsimberidou, A.M.3
  • 22
    • 33744492061 scopus 로고    scopus 로고
    • Antithymocyte globulin and ciclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes
    • Broliden P.A., Dahl I.M., Hast R., et al. Antithymocyte globulin and ciclosporine A as combination therapy for low-risk non-sideroblastic myelodysplastic syndromes. Haematologica 91 (2006) 70-667
    • (2006) Haematologica , vol.91 , pp. 70-667
    • Broliden, P.A.1    Dahl, I.M.2    Hast, R.3
  • 23
    • 33745968917 scopus 로고    scopus 로고
    • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    • Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108 (2006) 25-419
    • (2006) Blood , vol.108 , pp. 25-419
    • Cheson, B.D.1    Greenberg, P.L.2    Bennett, J.M.3
  • 24
    • 0037443455 scopus 로고    scopus 로고
    • Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome
    • Steensma D.P., Dispenzieri A., Moore S.B., Schroeder G., and Tefferi A. Antithymocyte globulin has limited efficacy and substantial toxicity in unselected anemic patients with myelodysplastic syndrome. Blood 101 (2003) 2156-2158
    • (2003) Blood , vol.101 , pp. 2156-2158
    • Steensma, D.P.1    Dispenzieri, A.2    Moore, S.B.3    Schroeder, G.4    Tefferi, A.5
  • 25
    • 7344223859 scopus 로고    scopus 로고
    • Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles
    • Molldrem J.J., Jiang Y.Z., Stetler-Stevenson M., Mavroudis D., Hensel N., and Barrett A.J. Haematological response of patients with myelodysplastic syndrome to antithymocyte globulin is associated with a loss of lymphocyte-mediated inhibition of CFU-GM and alterations in T-cell receptor Vbeta profiles. Br J Haematol 102 (1998) 22-1314
    • (1998) Br J Haematol , vol.102 , pp. 22-1314
    • Molldrem, J.J.1    Jiang, Y.Z.2    Stetler-Stevenson, M.3    Mavroudis, D.4    Hensel, N.5    Barrett, A.J.6
  • 26
    • 0034037280 scopus 로고    scopus 로고
    • Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia
    • Killick S.B., Marsh J.C., Gordon-Smith E.C., Sorlin L., and Gibson F.M. Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia. Br J Haematol 108 (2000) 91-582
    • (2000) Br J Haematol , vol.108 , pp. 91-582
    • Killick, S.B.1    Marsh, J.C.2    Gordon-Smith, E.C.3    Sorlin, L.4    Gibson, F.M.5
  • 27
    • 20244381363 scopus 로고    scopus 로고
    • Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a,,non-clonal" pattern of X-chromosome inactivation in bone marrow cells
    • Aivado M., Rong A., Stadler M., et al. Favourable resopnse to antithymocyte or antilymphocyte globulin in low-risk myelodysplastic syndrome patients with a,,non-clonal" pattern of X-chromosome inactivation in bone marrow cells. Eur J Haematol 68 (2002) 6-210
    • (2002) Eur J Haematol , vol.68 , pp. 6-210
    • Aivado, M.1    Rong, A.2    Stadler, M.3
  • 28
    • 0036720903 scopus 로고    scopus 로고
    • HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes
    • Saunthararajah Y., Nakamura R., Nam J.M., et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndromes. Blood 100 (2002) 4-1570
    • (2002) Blood , vol.100 , pp. 4-1570
    • Saunthararajah, Y.1    Nakamura, R.2    Nam, J.M.3
  • 29
    • 0141923848 scopus 로고    scopus 로고
    • A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes
    • Saunthararajah Y., Nakamura R., Wesley R., and Barrett A.J. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndromes. Blood 102 (2003) 7-3025
    • (2003) Blood , vol.102 , pp. 7-3025
    • Saunthararajah, Y.1    Nakamura, R.2    Wesley, R.3    Barrett, A.J.4
  • 30
    • 0037353935 scopus 로고    scopus 로고
    • A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life
    • Hellström-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 120 (2003) 46-1037
    • (2003) Br J Haematol , vol.120 , pp. 46-1037
    • Hellström-Lindberg, E.1    Gulbrandsen, N.2    Lindberg, G.3
  • 31
    • 33749438404 scopus 로고    scopus 로고
    • Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion
    • List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 355 (2006) 65-1456
    • (2006) N Engl J Med , vol.355 , pp. 65-1456
    • List, A.1    Dewald, G.2    Bennett, J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.